China-based medical technology company Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190) said on Friday that it has entered into a definitive agreement to acquire Germany-based Optimed Medizinische Instrumente GmbH in multiple steps, with an option to acquire 100% of the equity.

Optimed specialises in minimally invasive vascular and endourology devices, with a sales and service network spanning more than 70 countries and a broad portfolio in peripheral venous stenting supported by clinical evidence, including the STEVECO trial.

Zylox-Tonbridge said the transaction would establish an integrated global platform covering research and development, manufacturing and commercialisation, combining Optimed's European clinical relationships with Zylox-Tonbridge's existing capabilities. The deal is expected to accelerate the company's international strategy, broaden its product portfolio and scale global distribution, while fully leveraging its research and development platform to support future growth.

The group expects manufacturing and operational synergies across Germany and China, supported by an expanded manufacturing base in Germany to ensure reliable supply to European and global markets.

Following completion, sales, marketing and customer service teams will be integrated into a single global commercial organisation.